Publication:
Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders

dc.contributor.coauthorAbboud, Hesham
dc.contributor.coauthorSalazar-Camelo, Andrea
dc.contributor.coauthorGeorge, Naveen
dc.contributor.coauthorPlanchon, Sarah M.
dc.contributor.coauthorMatiello, Marcelo
dc.contributor.coauthorMealy, Maureen A.
dc.contributor.coauthorGoodman, Andrew
dc.contributor.coauthorGuthy-Jackson Fdn NMO Int Clinical
dc.contributor.kuauthorAltıntaş, Ayşe
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid11611
dc.date.accessioned2024-11-09T13:20:17Z
dc.date.issued2022
dc.description.abstractNeuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory conditions that primarily target the optic nerves, spinal cord, brainstem, and occasionally the cerebrum. NMOSD is characterized by recurrent attacks of visual, motor, and/or sensory dysfunction that often result in severe neurological deficits. In recent years, there has been a significant progress in relapse treatment and prevention but the residual disability per attack remains high. Although symptomatic and restorative research has been limited in NMOSD, some therapeutic approaches can be inferred from published case series and evidence from multiple sclerosis literature. In this review, we will discuss established and emerging therapeutic options for symptomatic treatment and restoration of function in NMOSD. We highlight NMOSD-specific considerations and identify potential areas for future research. The review covers pharmacologic, non-pharmacologic, and neuromodulatory approaches to neuropathic pain, tonic spasms, muscle tone abnormalities, sphincter dysfunction, motor and visual impairment, fatigue, sleep disorders, and neuropsychological symptoms. In addition, we briefly discuss remyelinating agents and mesenchymal stem cell transplantation in NMOSD.
dc.description.fulltextYES
dc.description.indexedbyWoS
dc.description.indexedbyPubMed
dc.description.issue4
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipOpen access funding provided by the Guthy-Jackson Charitable Foundation
dc.description.versionPublisher version
dc.description.volume269
dc.formatpdf
dc.identifier.doi10.1007/s00415-021-10783-4
dc.identifier.eissn1432-1459
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR03856
dc.identifier.issn0340-5354
dc.identifier.linkhttps://doi.org/10.1007/s00415-021-10783-4
dc.identifier.quartileQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14288/3195
dc.keywordsNMOSDN
dc.keywordsEuromyelitis optica
dc.keywordsNMO
dc.keywordsSymptomatic
dc.keywordsNeuropathic pain
dc.keywordsTonic spasms
dc.keywordsRemyelination
dc.keywordsMesenchymal stem cells
dc.languageEnglish
dc.publisherSpringer
dc.relation.grantnoNA
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10722
dc.sourceJournal of Neurology
dc.subjectNeurosciences and neurology
dc.titleSymptomatic and restorative therapies in neuromyelitis optica spectrum disorders
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-8524-5087
local.contributor.kuauthorAltıntaş, Ayşe

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10722.pdf
Size:
785.65 KB
Format:
Adobe Portable Document Format